FAQs Archive - Aronora Inc.

Skip to content

Search for:

ABOUT
- MISSION
- LEADERSHIP
PIPELINE
NEWS & MEDIA
CAREERS
CONTACT

Search for:

Aronora, Inc.

Aronora’s mission is to develop safe, paradigm shifting drugs to treat life-threatening blood diseases.

Quick Links

Home
About
Pipeline
News & Media
Careers
Contact

Connect With Us

1818 SW 4th Ave.
Suite 102
Portland, OR 97201

(503) 530-6842

Email Us

All Materials © Aronora, Inc.Web Development by Tumbleweed Creative

AB023 (Gruticibart) Publications

Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Pfeffer MA, Kohs TCL, Vu HH, Jordan KR, Si Han Wang J, Lorentz CU, Tucker EI, Puy C, Olson SR, DeLoughery TG, Hinds MT, Keshari RS, Gailani D, Lupu F, McCarty OJT, Shatzel JJ. Arterioscler Thromb Vasc Biol. 2023 Nov 16. doi: 10.1161/ATVBAHA.123.319692. Online ahead of print.

Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation. Meyer AD, Thorpe CR, Fraker T, Cancio T, Rocha J, Willis RP, Cap AP, Gailani D, Shatzel JJ, Tucker EI, McCarty OJT. ASAIO J. 2023 Oct 6. doi: 10.1097/MAT.0000000000002048. Online ahead of print.

Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial. Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds M, McCarty OJT, Gailani D, Weitz JI, Gruber A. Blood. 2021 Dec 2;138(22):2173-2184.

Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Lorentz CU, Verbout NG, Wallisch M, Hagen MW, Shatzel JJ, Olson SR, Puy C, Hinds MT, McCarty OJT, Gailani D, Gruber A, Tucker EI. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.

AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. Chan NC, Weitz JI. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):533-535.

Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, Hinds MT, Fazio S, Monia BP, Gailani D, Gruber A, Tavori H, McCarty OJT.J Thromb Haemost. 2021 Apr;19(4):1001-1017.

Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death.Silasi R, Keshari RS, Lupu C, Van Rensburg WJ, Chaaban H, Regmi G, Shamanaev A, Shatzel JJ, Puy C, Lorentz CU, Tucker EI, Gailani D, Gruber A, McCarty OJT, Lupu F. Blood Adv. 2019 Feb 26;3(4):658-669.

Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Tucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, Gruber A. Blood. 2012 May 17;119(20):4762-8.

Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Luo D, Szaba FM, Kummer LW, Johnson LL, Tucker EI, Gruber A, Gailani D, Smiley ST. Infect Immun. 2012 Jan;80(1):91-9.

A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, Gailani D. Blood. 2010 Nov 11;116(19):3981-9.

Feedback controversy stops here. Meijers JC. Blood. 2009 Jul 9;114(2):235.

AB023 (Gruticibart) Clinical Trials

Phase 2: Safety and Efficacy Study of AB023 in End Stage Renal Disease Patients on Chronic Hemodialysis

Phase 2: AB023 (Gruticibart) for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Phase 1: Safety and Tolerability Study of AB023 in Healthy Adult Subjects

AB002 (E-WE thrombin) Clinical Trials

Phase 2: Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Phase 1: Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

AB054 (recopimab) Publications

Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus.Silasi R, Keshari RS, Regmi G, Lupu C, Georgescu C, Simmons JH, Wallisch M, Kohs TCL, Shatzel JJ, Olson SR, Lorentz C, Puy C, Tucker EI, Gailani D, Strickland S, Gruber A, McCarty O, Lupu F. Blood. 2021 Feb 17:blood.2020009345. doi: 10.1182/blood.2020009345.

Crystalizing our view of the contact system. Tucker EI. Blood. 2020 Oct 1;136(14):1576-1577.

Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. Wallisch M, Lorentz CU, Lakshmanan HHS, Johnson J, Carris MR, Puy C, Gailani D, Hinds MT, McCarty OJT, Gruber A, Tucker EI. Res Pract Thromb Haemost. 2020 Feb 11;4(2):205-216.

A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Ivanov I, Matafonov A, Sun MF, Mohammed BM, Cheng Q, Dickeson SK, Kundu S, Verhamme IM, Gruber A, McCrae K, Gailani D. Blood. 2019 Mar 7;133(10):1152-1163.

Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renné T, Morrissey JH, Gruber A, Gailani D. Blood. 2014 Mar 13;123(11):1739-46.

AB062 Publications

Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets. Barrett TJ, Wu BG, Revenko AS, MacLeod AR, Segal LN, Berger JS.J Thromb Haemost. 2020 Jul;18(7):1773-1782.

Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Shirai T, Revenko AS, Tibbitts J, Ngo ATP, Mitrugno A, Healy LD, Johnson J, Tucker EI, Hinds MT, Coussens LM, McCarty OJT, Monia BP, Gruber A. Blood Adv. 2019 Oct 22;3(20):3080-3091

Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, McCarty OJ, Gruber A, Hanson SR. Sci Transl Med. 2010 Jun 23;2(37):37ra45.

Osocimab Publications

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. JAMA. 2020 Jan 14;323(2):130-139.

Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. Schaefer M, Buchmueller A, Dittmer F, Straßburger J, Wilmen A. J Mol Biol. 2019 Dec 6;431(24):4817-4833.

Osocimab Clinical Trials

Phase 2: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Phase 2: FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 1: End-stage Renal Disease (ESRD) Pilot Study

AB002 (E-WE thrombin) Publications

The protein C activator AB002 rapidly interrupts thrombus development in baboons. Tucker EI, Verbout NG, Markway BD, Wallisch M, Lorentz CU, Hinds MT, Shatzel JJ, Pelc LA, Wood DC, McCarty OJT, Di Cera E, Gruber A. Blood. 2020 Feb 27;135(9):689-699.

Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Verbout NG, Yu X, Healy LD, Phillips KG, Tucker EI, Gruber A, McCarty OJ, Offner H. Metab Brain Dis. 2015 Feb;30(1):57-65.

Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Vicente CP, Weiler H, Di Cera E, Tollefsen DM. Thromb Res. 2012 Oct;130(4):646-8.

Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Berny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A. Stroke. 2011 Jun;42(6):1736-41.

The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di Cera E, Wagner DD, Degen JL. Blood. 2011 Jun 9;117(23):6326-37.

Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Berny MA, White TC, Tucker EI, Bush-Pelc LA, Di Cera E, Gruber A, McCarty OJ. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):329-34.

Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Gruber A, Marzec UM, Bush L, Di Cera E, Fernández JA, Berny MA, Tucker EI, McCarty OJ, Griffin JH, Hanson SR.Blood. 2007 May 1;109(9):3733-40.

The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. Gruber A, Cantwell AM, Di Cera E, Hanson SR. J Biol Chem. 2002 Aug 2;277(31):27581-4.